Owkin

Rounds and research, on one timeline

1. 2025-12-09
   Research

   Level 3 · Checked against existing evidence

   Owkin's slide-reading recurrence test separated breast-cancer patients better than two commercial gene assays in two hospital cohorts, on 7 and 42 recorded recurrences

   Oncotype DX decides whether a woman gets chemotherapy, so a model that reads the slide the hospital already has would be cheaper and need no tissue sent away. This is not yet evidence it can take that decision: the analysis is the company's own, looking back at archived slides, and 7 recurrences in one cohort cannot separate two tests. The abstract itself says the test 'may support' de-escalation.

   Timeline entry →doi.org ↗

2. 2022-06-07Series B
   Round

   part of $80M in aggregate with an upfront fee; equity share not broken out

   For: data generation, incl. spatial single-cell omics

   Data generation

   Named Series B-1 by the company. Owkin's FAQ gives stage totals: seed $2.1M, Series A $72M, Series B $230M, $304.1M in all.

   Lead · Bristol Myers Squibb

   Announced by the company · owkin.com ↗

3. 2021-11-18Strategic
   Round

   $180M$1B · stated by company

   For: alongside an oncology collaboration in four cancers

   Commercial roll-out

   Owkin says the investment makes it valued at more than $1B; the exact figure is not given.

   Lead · Sanofi

   Announced by the company · owkin.com ↗

4. 2020-05Series A extension
   Round

   $25M

   For: grow its catalogue of models and sign more hospital and academic partners, who supply its data

   Models and platformData generation

   A Series A extension; existing investors named are GV, F-Prime Capital and Eight Roads Ventures.

   Bpifrance Large Venture ✓Cathay Innovation ✓MACSF ✓

   On the deal: Audrey Cacaly (Project Manager, Bpifrance Large Venture); Jacky Abitbol (Partner, Cathay Innovation); Laurent Higueret (Investment Director, Bpifrance Large Venture); Maïlys Ferrère (Fund Director, Bpifrance Large Venture); Stanislas Subra (Head of Venture Capital Investments, MACSF); Thierry Houselstein (Medical Director, MACSF)

   The investor's own page says · MACSF: since 2020

   By this date the record held 1 research entry, highest level 3

   Reported by ActuIA · actuia.com ↗

5. 2019-10-07
   Research

   Level 3 · Checked against existing evidence

   Owkin's MesoNet predicts mesothelioma survival from whole-slide pathology images with no pathologist-marked regions, validated on a French cohort and on TCGA

   An early case of a startup's model pointing to new tissue features. It is retrospective on stored slides, not a prospective test or a clinical decision.

   Timeline entry →doi.org ↗

6. 2019-03-07Round (unnamed)
   Round

   more than $15 million (FrenchWeb)

   Not stated

   The release names the investors but no amount; the figure is FrenchWeb's own, 'according to our information' (frenchweb.fr, 2019-05-14), which calls it the close of the Series A.

   Co-lead · F-Prime Capital ✓Co-lead · Eight Roads VenturesGV ✓Cathay Innovation ✓NJF Capital ✓

   Announced by the company · cathayinnovation.com ↗

7. 2018-01-16Series A
   Round

   $11M

   For: scale its OWKIN Socrates platform, build partnerships with healthcare organisations and fund internal growth

   Models and platformCommercial roll-out

   Brought total financing to $13.1M in one year.

   Lead · Otium CapitalCathay Innovation ✓Plug and PlayNJF Capital ✓

   On the deal: Bruno Raillard (Partner, Otium Capital, joins the board); Nicole Junkermann (Founder, NJF Capital, joins the board); Pierre-Edouard Stérin (Founder, Otium Capital)

   Announced by the company · cathaycapital.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →